114M0 First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement

“…In squamous tumors, OS was numerically higher with PD-L1 inhibitors (Table 5). -------------------------------------- ------------------------------------- ≥65 years HR = 0.48 (95% CI [0.30, 0.76]) [18] ---------------------------------------Men HR = 0.50 (95% CI [0.36, 0.69]) [18] Women HR = 1.11 (95% CI [0.49, 2.52]) [18] ---------------------------------------ECOG PS score = 0 HR = 0.77 (95% CI [0.41, 1.44]) [18] ECOG PS score = 1 HR = 0.54 (95% CI [0.38, 0.76]) [18] - --------------------------------------Squamous HR = 0.48 (95% CI [0.30, 0.77]) [18] Non-squamous HR = 0.60 (95% CI [0.44, 0.83]) [18] ---------------------------------------Brain metastases HR = 0.42 (95% CI [0.20, 0.87]) [27] No brain metastases HR = 0.60 (95% CI [0.44, 0.83]) [18] ---------------------------------------Locally advanced HR = 0.67 (95% CI [0.38, 1.17]) [28] <65 years HR = 0.60 (95% CI [0.38, 0.96]) [20] ≥65 years HR = 0.64 (95% CI [0.42, 0.98]) [20] <75 years HR = 0.71 (95% CI [0.59, 0.87]) [26] ≥75 years HR = 0.41 (95% CI [0.23, 0.73]) [26] ---------------------------------------Men HR = 0.54 (95% CI [0.36, 0.79]) [20] Women HR = 0.95 (95% CI [0.56, 1.62]) [20] - --------------------------------------ECOG PS score = 0 HR = 0.78 (95% CI [0.44, 1.37]) [20] ECOG PS score = 1 HR = 0.56 (95% CI [0.39, 0.81]) [20] - --------------------------------------Squamous HR = 0.73 (95% CI [0.28, 1.39]) [20] Non-squamous HR = 0.58 (95% CI [0.41, 0.83]) [20] ---------------------------------------Brain metastases HR = 0.73 (95% CI [0.20, 2.62]) [20] No brain metastases HR = 0.64 (95% CI [0.46, 0.88]) [20] Progressionfree survival -<65 years HR = 0.51 (95% CI [0.37, 0.69]) [18] ≥65 years HR = 0.60 (95% CI [0.43, 0.84]) [18] ---------------------------------------Men HR = 0.50 (95% CI [0.40, 0.64]) [18] Women HR = 0.79 (95% CI [0.43, 1.46]) …”

“…On the other hand, post hoc subgroup analysis in locally advanced NSCLC patients from the CEMI pivotal trial (Table 5) demonstrated improved OS and PFS with first-line CEMI compared with chemotherapy [28]. Therefore, the experts encourage clinicians to consider CEMI in unresectable, locally advanced NSCLC patients who are not candidates for radical chemoradiotherapy.…”

“…The CEMI trial included a notable proportion of unresectable locally advanced NSCLC patients who were not candidates for definitive chemoradiation (15% in the PD-L1 ≥50% population and 16% in the intention-to-treat population) [18]. In a post-hoc analysis, first line CEMI monotherapy demonstrated improved survival benefits compared with chemotherapy [28]. Considering these data, the expert panel supports the inclusion of unresectable, locally advanced NSCLC patients who are not candidates for radical chemoradiotherapy for CEMI treatment.…”

Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and Considerations

“…Tumor response was 48.9% in the cemiplimab group versus 31% in the chemotherapy group (OR 2.08; 95% CI 0.88–4.95). 8 Patients with treated, clinically stable brain metastases at baseline were evaluated as well. Median OS was NE in the cemiplimab group versus 20.7 months in the chemotherapy group (HR 0.42; 95% CI 0.20–0.87).…”